Q Therapeutics, Inc. - FORM 10-Q - XML - IDEA: XBRL DOCUMENT - November 13, 2012

Attached files
FileFilename
XML - IDEA: XBRL DOCUMENT - Q Therapeutics, Inc.R15.htm
XML - IDEA: XBRL DOCUMENT - Q Therapeutics, Inc.R7.htm
10-Q - Q Therapeutics, Inc.form10q.htm
XML - IDEA: XBRL DOCUMENT - Q Therapeutics, Inc.R20.htm
XML - IDEA: XBRL DOCUMENT - Q Therapeutics, Inc.R10.htm
XML - IDEA: XBRL DOCUMENT - Q Therapeutics, Inc.R5.htm
XML - IDEA: XBRL DOCUMENT - Q Therapeutics, Inc.R21.htm
XML - IDEA: XBRL DOCUMENT - Q Therapeutics, Inc.R16.htm
XML - IDEA: XBRL DOCUMENT - Q Therapeutics, Inc.R14.htm
XML - IDEA: XBRL DOCUMENT - Q Therapeutics, Inc.R13.htm
XML - IDEA: XBRL DOCUMENT - Q Therapeutics, Inc.R19.htm
XML - IDEA: XBRL DOCUMENT - Q Therapeutics, Inc.R23.htm
XML - IDEA: XBRL DOCUMENT - Q Therapeutics, Inc.R11.htm
XML - IDEA: XBRL DOCUMENT - Q Therapeutics, Inc.R12.htm
XML - IDEA: XBRL DOCUMENT - Q Therapeutics, Inc.R4.htm
XML - IDEA: XBRL DOCUMENT - Q Therapeutics, Inc.R18.htm
XML - IDEA: XBRL DOCUMENT - Q Therapeutics, Inc.R1.htm
XML - IDEA: XBRL DOCUMENT - Q Therapeutics, Inc.R17.htm
XML - IDEA: XBRL DOCUMENT - Q Therapeutics, Inc.R3.htm
XML - IDEA: XBRL DOCUMENT - Q Therapeutics, Inc.R24.htm
XML - IDEA: XBRL DOCUMENT - Q Therapeutics, Inc.R22.htm
XML - IDEA: XBRL DOCUMENT - Q Therapeutics, Inc.R6.htm
XML - IDEA: XBRL DOCUMENT - Q Therapeutics, Inc.R2.htm
XML - IDEA: XBRL DOCUMENT - Q Therapeutics, Inc.R8.htm
EXCEL - IDEA: XBRL DOCUMENT - Q Therapeutics, Inc.Financial_Report.xls
XML - IDEA: XBRL DOCUMENT - Q Therapeutics, Inc.R9.htm
EX-32.2 - Q Therapeutics, Inc.ex32-2.htm
EX-32.1 - Q Therapeutics, Inc.ex32-1.htm
EX-31.2 - Q Therapeutics, Inc.ex31-2.htm
EX-31.1 - Q Therapeutics, Inc.ex31-1.htm
EX-14.1 - Q Therapeutics, Inc.ex14-1.htm
EX-3.2 - Q Therapeutics, Inc.ex3-2.htm
EX-3.1 - Q Therapeutics, Inc.ex3-1.htm
v2.4.0.6
Subsequent Events (Details Narrative) (USD $)
 9 Months Ended
Sep. 30, 2012
Common stock issued under subsequent events 50,000
Monthly cash retainer limit $ 10,000
Authorized to issue additional warrants 250,000
Percentage of commission on offering proceeds for financial advisor 7.00%
Percentage of authorized to purchase common stock 10.00%
Minimum [Member]
  
Warrant exercise price $ 1.25
Maximum [Member]
  
Warrant exercise price $ 2.75

User Contributions:

Comment about this document or add new information about this topic:

CAPTCHA


This web site and associated pages are not associated with, endorsed by, or sponsored by Q Therapeutics, Inc. and has no official or unofficial affiliation with Q Therapeutics, Inc.


Based on public records. Inadvertent errors are possible.
Faqs.org does not guarantee the accuracy or timeliness of any information on this site.  Use at your own risk. This website is not associated with the SEC

Some parts © 2013 Advameg, Inc.